Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602896 | 1.00 | MEN1 (0.36) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| Bromide SCHEMBL3930965 | 0.99 | MEN1 (0.36) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| Bromide SCHEMBL3930970 | 0.99 | MEN1 (0.36) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| SCHEMBL13717108 | 0.93 | MEN1 (0.41) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| SCHEMBL4584737 | 0.88 | TBXAS1 (0.37) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| SCHEMBL4584627 | 0.88 | KDM4A (0.34) | KDM4AKDM2A | |
| SCHEMBL4584622 | 0.88 | KDM4A (0.34) | KDM4AKDM2A | |
| SCHEMBL4583954 | 0.88 | TBXAS1 (0.37) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| SCHEMBL4583949 | 0.88 | TBXAS1 (0.37) | MEN1KMT2ALMNAMAPK1TBXAS1 | |
| Bromide SCHEMBL3929432 | 0.87 | TBXAS1 (0.36) | MEN1KMT2ALMNAMAPK1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569079-B2 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1980558-A1 | Polycationic monochromophoric compounds of hydrazone type, dyeing compositions comprising same and dyeing method | L'Oréal (FR) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | KRT18, CKMT1A; CKMT1B, XRCC5 | MEN1 2823/4885KMT2A 459/4885LMNA 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.